Squamous Cell Carcinoma of Penis

MONDO:0018352 Pathograph 8 penile carcinoma squamous cell carcinoma

Squamous cell carcinoma of penis is a penile epithelial malignancy arising chiefly from squamous epithelium of the glans, coronal sulcus, or foreskin. It is the dominant histologic form of penile cancer and has HPV-associated and HPV-independent etiologic pathways. Chronic genital inflammation, poor genital hygiene, lack of neonatal circumcision, HPV infection, penile intraepithelial neoplasia, and somatic alterations affecting TP53, CDKN2A, PIK3CA, and immune-checkpoint biomarkers contribute to malignant transformation, local invasion, and inguinal nodal spread.

Ask OpenScientist

Ask a research question about Squamous Cell Carcinoma of Penis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
1
Definitions
0
Inheritance
4
Pathophysiology
1
Histopathology
3
Phenotypes
8
Pathograph
3
Genes
4
Treatments
4
Subtypes
0
Differentials
0
Datasets
3
Trials
0
Models
1
Deep Research
📘

Definitions

1
Clinicopathologic definition
Penile squamous cell carcinoma is a penile neoplasm of squamous cell origin, diagnosed by clinical examination of the primary lesion and regional nodes followed by tissue biopsy for histologic classification.
CASE_DEFINITION Adult genitourinary oncology
Show evidence (2 references)
PMID:38841163 SUPPORT Human Clinical
"Penile Squamous Cell Carcinoma (PSCC) represents approximately 95% of all penile neoplasms."
This review identifies PSCC as the dominant penile neoplasm histology.
PMID:38841163 SUPPORT Human Clinical
"Diagnosis of PSCC is done through clinical examination, including lymph node palpation, followed by a biopsy, which is essential for the classification."
This supports the biopsy-based clinicopathologic definition and nodal examination component.
◆

Subtypes

4
HPV-associated penile squamous cell carcinoma
Molecular subtype associated with high-risk human papillomavirus infection, viral oncogene-mediated cell-cycle dysregulation, and distinct immune-checkpoint biomarker patterns.
Show evidence (1 reference)
PMID:37565840 SUPPORT Human Clinical
"HPV-positive and HPV-negative pSCCs are molecularly distinct tumors."
The cohort supports HPV-associated PSCC as a molecularly distinct subtype.
HPV-independent penile squamous cell carcinoma
Molecular subtype not driven by HPV, often linked to chronic inflammatory penile disease and somatic alterations affecting tumor suppressor and cell-cycle pathways.
Show evidence (1 reference)
PMID:37565840 SUPPORT Human Clinical
"HPV-positive and HPV-negative pSCCs are molecularly distinct tumors."
This supports a distinction between HPV-positive and HPV-negative PSCC molecular subsets.
Verrucous penile squamous cell carcinoma
Well-differentiated, exophytic variant with locally destructive growth and generally lower metastatic potential than conventional invasive PSCC.
Basaloid penile squamous cell carcinoma
Aggressive histologic variant often associated with high-risk HPV and basaloid morphology.
⚙

Pathophysiology

4
HPV-Associated Epithelial Oncogenesis
Persistent high-risk HPV infection promotes malignant transformation of penile squamous epithelium and creates an HPV-associated PSCC subset with distinct immune-checkpoint biomarker features.
penile squamous epithelial cell link
response to virus link ⚠ ABNORMAL
penis epithelium link
Downstream
Invasive Squamous Cell Proliferation HPV-associated oncogenesis independently converges on malignant squamous proliferation rather than causing the somatic driver alterations enriched in HPV-negative tumors.
Immune-Checkpoint Biomarker Enrichment HPV status stratifies TMB and immune-checkpoint biomarker patterns.
Show evidence (2 references)
PMID:39339000 SUPPORT Human Clinical
"Approximately 40% of penile tumors are associated with human papillomavirus (HPV) infection."
This supports HPV-associated oncogenesis as a major upstream mechanism in a substantial subset of penile tumors.
PMID:37565840 SUPPORT Human Clinical
"Approximately half of pSCC cases are associated with human papillomavirus (HPV) infection."
The genomic cohort background independently supports frequent HPV-associated PSCC.
Somatic Cell-Cycle Driver Alteration
PSCC commonly carries somatic alterations in TP53, CDKN2A, and PIK3CA, disrupting checkpoint control and growth/survival signaling in transformed penile squamous cells.
TP53 link CDKN2A link PIK3CA link
cell cycle checkpoint signaling link ↓ DECREASED cell population proliferation link ↑ INCREASED
Downstream
Invasive Squamous Cell Proliferation Driver alterations support malignant proliferation and invasion.
Show evidence (1 reference)
PMID:37565840 SUPPORT Human Clinical
"revealed TP53 (46%), CDKN2A (26%), and PIK3CA (25%) to be the most common mutations."
The NGS cohort directly supports these recurrent somatic driver genes in PSCC.
Immune-Checkpoint Biomarker Enrichment
A substantial subset of PSCC shows PD-L1 positivity and high tumor mutational burden, particularly in HPV-positive tumors, providing a biomarker rationale for immune-checkpoint inhibitor trials.
negative regulation of T cell mediated immunity link ↑ INCREASED
Show evidence (2 references)
PMID:37565840 SUPPORT Human Clinical
"Overall, 51% of tumors were PD-L1+, 10.7% had high TMB, and 1.1% had mismatch repair-deficient (dMMR)/MSI-high status."
This supports PD-L1 and TMB as immune-checkpoint-related biomarkers in PSCC.
PMID:37565840 SUPPORT Human Clinical
"Increased tumor mutational burden is associated with HPV-positive tumors, and could serve as a biomarker for predicting therapeutic response to ICI-based therapies."
This supports the HPV-associated immune biomarker rationale for ICI-based therapy selection.
Invasive Squamous Cell Proliferation
Transformed penile squamous cells proliferate locally and may disseminate to inguinal lymph nodes, making nodal assessment central to staging and prognosis.
penile squamous epithelial cell link
cell population proliferation link ↑ INCREASED
glans penis link
Show evidence (2 references)
PMID:38841163 SUPPORT Human Clinical
"Lymph node involvement is a common finding at first presentation and investigation of spread to deep nodes is important and can be done with the aid of PET-CT."
This supports inguinal/deep nodal spread as a clinically important manifestation of invasive PSCC.
PMID:39272796 SUPPORT Human Clinical
"The diagnosis of occult inguinal lymph node metastasis in clinically node-negative invasive penile squamous cell carcinoma (PSCC) has remained a challenge, with substantial perioperative complications."
This supports occult inguinal lymph-node metastasis as a key invasive disease concern.
✶

Histopathology

1
Squamous Cell Carcinoma Histology
Squamous cell carcinoma is the dominant penile cancer histology and is classified further by HPV/PeIN-associated and non-HPV-related pathways and histologic variants.
Show evidence (1 reference)
PMID:38841163 SUPPORT Human Clinical
"While the penis can be affected by sarcomas, basal cell carcinomas or even melanoma, Penile Squamous Cell Carcinoma (PSCC) represents approximately 95% of all penile neoplasms."
This supports squamous cell carcinoma as the dominant penile neoplasm histology.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Squamous Cell Carcinoma of Penis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

3
Variable Penile Clinical Presentation Clinical HP:0000078
Show evidence (1 reference)
PMID:38841163 SUPPORT Human Clinical
"For such a rare condition PSCC can present in many different forms clinically making diagnosis no easy feat."
This supports variable clinical presentation as a practical phenotype of PSCC.
Primary Penile Lesion Clinical HP:0000032
Show evidence (1 reference)
PMID:38841163 SUPPORT Human Clinical
"Penile Squamous Cell Carcinoma (PSCC) represents approximately 95% of all penile neoplasms."
This supports PSCC as a primary penile neoplastic abnormality.
Inguinal Lymphadenopathy Clinical HP:0034751
Show evidence (2 references)
PMID:38841163 SUPPORT Human Clinical
"Diagnosis of PSCC is done through clinical examination, including lymph node palpation, followed by a biopsy, which is essential for the classification."
The diagnostic workflow includes lymph-node palpation, supporting nodal enlargement as a clinically assessed manifestation.
PMID:39272796 SUPPORT Human Clinical
"Although DSLNB, if available, has been endorsed as the preferred method for nodal staging in patients with invasive PSCC and no palpable inguinal lymphadenopathy in the recent penile cancer guidelines, its utilization has been quite limited so far."
This directly references palpable inguinal lymphadenopathy status in PSCC nodal staging.
🧬

Genetic Associations

3
TP53 (Somatic Driver Mutation)
Show evidence (1 reference)
PMID:37565840 SUPPORT Human Clinical
"revealed TP53 (46%), CDKN2A (26%), and PIK3CA (25%) to be the most common mutations."
This cohort identifies TP53 as the most common recurrent somatic alteration in PSCC.
CDKN2A (Somatic Driver Mutation)
Show evidence (1 reference)
PMID:37565840 SUPPORT Human Clinical
"CDKN2A mutations (0% vs. 37.5%) were exclusive to HPV16/18- tumors."
This supports CDKN2A mutation as a recurrent HPV-negative PSCC molecular feature.
PIK3CA (Somatic Driver Mutation)
Show evidence (1 reference)
PMID:37565840 SUPPORT Human Clinical
"revealed TP53 (46%), CDKN2A (26%), and PIK3CA (25%) to be the most common mutations."
This cohort identifies PIK3CA among the most common recurrent somatic alterations in PSCC.
💊

Treatments

4
Surgical Tumor Removal
Action: surgical procedure MAXO:0000004
Local surgical excision, glansectomy, or penectomy provides primary local control when disease is anatomically resectable, but can substantially affect quality of life.
Show evidence (1 reference)
PMID:38841163 SUPPORT Human Clinical
"Surgical removal of the tumor is considered the most effective however can lead to severe decrease of quality of life."
This review supports surgery as the core local treatment and notes the associated quality-of-life burden.
Platinum-Based Chemotherapy
Action: chemotherapy MAXO:0000647
Agent: platinum compound ↗
Platinum-based systemic chemotherapy is used for fixed or bulky nodal disease and distant metastatic PSCC.
Show evidence (1 reference)
PMID:38841163 SUPPORT Human Clinical
"Chemotherapy is used in the case of fixed or bulky lymph nodes, where surgery is not indicated, and for distant metastasis."
This supports chemotherapy in advanced nodal or metastatic PSCC.
Radiation Therapy
Action: radiation therapy MAXO:0000014
Radiation therapy is used in selected PSCC contexts, with particular relevance in HPV-positive disease and organ-preservation strategies.
Show evidence (1 reference)
PMID:38841163 SUPPORT Human Clinical
"Radiation therapy is particularly effective in the case of HPV-positive PSCC."
The review supports radiation therapy as a treatment modality with relevance in HPV-positive PSCC.
Immune Checkpoint Inhibitor Combinations
Action: pharmacotherapy MAXO:0000058
Agent: pembrolizumab ↗
Checkpoint-inhibitor combinations are investigational for advanced PSCC and include pembrolizumab-containing regimens motivated by PD-L1/TMB biomarker findings and early clinical trial experience.
Mechanism Target:
MODULATES Immune-Checkpoint Biomarker Enrichment — Immune-checkpoint inhibitor combinations are intended to restore anti-tumor immune activity in biomarker-selected or advanced PSCC.
Show evidence (2 references)
DOI:10.3390/cancers16112086 SUPPORT Human Clinical
"We conclude that antibody-drug conjugates are especially promising, as are the combinations of immune checkpoint inhibitors with other types of drugs."
This review supports immune-checkpoint inhibitor combinations as a promising investigational therapeutic direction in advanced penile cancer.
clinicaltrials:NCT04224740 SUPPORT Human Clinical
"This is a phase II clinical trial evaluating activity, safety and patients reported outcomes of first-line pembrolizumab plus cisplatin (or carboplatin) plus 5-FU for patients with advanced penile squamous cell carcinoma."
The trial record directly supports pembrolizumab as an immune-checkpoint agent used in combination therapy for advanced PSCC.
🌍

Environmental Factors

2
Poor Genital Hygiene and Lack of Neonatal Circumcision
Hygiene barriers and absence of neonatal circumcision are clinical risk contexts that can coexist with chronic local inflammation and HPV exposure.
Show evidence (1 reference)
PMID:38841163 SUPPORT Human Clinical
"The list of associated risk factors is long and includes among others, lack of neonatal circumcision, poor genital hygiene, socioeconomic status, history of human papillomavirus (HPV) infection and penile intraepithelial neoplasia (PeIN)."
This exact abstract sentence lists lack of neonatal circumcision and poor genital hygiene among PSCC-associated risk factors.
Penile Intraepithelial Neoplasia
Penile intraepithelial neoplasia is a precursor/risk lesion incorporated into PSCC classification and management.
Show evidence (1 reference)
PMID:38841163 SUPPORT Human Clinical
"HPV and PeIN are indisputable risk factors, and both also form part of the classification system for PSCC."
This directly supports PeIN as a risk lesion and classification-relevant precursor context.
🔬

Clinical Trials

3
NCT04224740 PHASE_II COMPLETED
Phase II HERCULES/LACOG 0218 trial of first-line pembrolizumab plus cisplatin or carboplatin plus 5-FU for advanced penile squamous cell carcinoma. ClinicalTrials.gov API listed status as COMPLETED on 2026-05-10.
Target Phenotypes: advanced penile squamous cell carcinoma
Show evidence (1 reference)
clinicaltrials:NCT04224740 SUPPORT Human Clinical
"This is a phase II clinical trial evaluating activity, safety and patients reported outcomes of first-line pembrolizumab plus cisplatin (or carboplatin) plus 5-FU for patients with advanced penile squamous cell carcinoma."
The ClinicalTrials.gov summary directly supports the study intervention and advanced PSCC population.
NCT02837042 PHASE_II TERMINATED
Phase II trial of pembrolizumab for advanced penile squamous cell carcinoma after prior chemotherapy. ClinicalTrials.gov API listed status as TERMINATED on 2026-05-10.
Target Phenotypes: advanced penile squamous cell carcinoma
Show evidence (1 reference)
clinicaltrials:NCT02837042 SUPPORT Human Clinical
"Penile squamous cell carcinoma (PSCC) is relatively rare but exhibits higher incidences in less developed countries. PSCC is a highly aggressive malignancy characterized by early spread. Pembrolizumab has recently been FDA-approved for the treatment of melanoma but will serve as the..."
The ClinicalTrials.gov summary supports pembrolizumab as the investigational therapy for advanced PSCC in this trial.
NCT06353906 PHASE_II RECRUITING
Phase II PRIAM study of induction carboplatin/paclitaxel plus pembrolizumab for locoregionally advanced, node-positive, resectable squamous cell carcinoma of the penis. ClinicalTrials.gov API listed status as RECRUITING on 2026-05-10.
Target Phenotypes: node-positive squamous cell carcinoma of the penis
Show evidence (1 reference)
clinicaltrials:NCT06353906 SUPPORT Human Clinical
"This is a single-armed, single-centre, non-blinded phase II trial to assess efficacy of induction chemo-immunotherapy for resectable node-positive squamous cell carcinoma of the penis"
The ClinicalTrials.gov summary supports the population and chemo-immunotherapy intervention for this recruiting phase II study.
{ }

Source YAML

click to show 
name: Squamous Cell Carcinoma of Penis
creation_date: "2026-05-10T18:39:20Z"
updated_date: "2026-05-10T19:49:37Z"
synonyms:
- Penile squamous cell carcinoma
- Squamous cell carcinoma of the penis
- Penile squamous cell cancer
- PSCC
description: >-
  Squamous cell carcinoma of penis is a penile epithelial malignancy arising
  chiefly from squamous epithelium of the glans, coronal sulcus, or foreskin.
  It is the dominant histologic form of penile cancer and has HPV-associated
  and HPV-independent etiologic pathways. Chronic genital inflammation, poor
  genital hygiene, lack of neonatal circumcision, HPV infection, penile
  intraepithelial neoplasia, and somatic alterations affecting TP53, CDKN2A,
  PIK3CA, and immune-checkpoint biomarkers contribute to malignant
  transformation, local invasion, and inguinal nodal spread.
categories:
- Urogenital Cancer
- Solid Tumor
- Squamous Cell Carcinoma
- HPV-Related Cancer
disease_term:
  preferred_term: squamous cell carcinoma of penis
  term:
    id: MONDO:0018352
    label: squamous cell carcinoma of penis
parents:
- penile carcinoma
- squamous cell carcinoma
definitions:
- name: Clinicopathologic definition
  definition_type: CASE_DEFINITION
  description: >-
    Penile squamous cell carcinoma is a penile neoplasm of squamous cell
    origin, diagnosed by clinical examination of the primary lesion and regional
    nodes followed by tissue biopsy for histologic classification.
  scope: Adult genitourinary oncology
  evidence:
  - reference: PMID:38841163
    reference_title: "A comprehensive review of current knowledge on penile squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Penile Squamous Cell Carcinoma (PSCC) represents approximately 95% of all
      penile neoplasms.
    explanation: >-
      This review identifies PSCC as the dominant penile neoplasm histology.
  - reference: PMID:38841163
    reference_title: "A comprehensive review of current knowledge on penile squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnosis of PSCC is done through clinical examination, including lymph
      node palpation, followed by a biopsy, which is essential for the
      classification.
    explanation: >-
      This supports the biopsy-based clinicopathologic definition and nodal
      examination component.
has_subtypes:
- name: HPV-Associated PSCC
  display_name: HPV-associated penile squamous cell carcinoma
  description: >-
    Molecular subtype associated with high-risk human papillomavirus infection,
    viral oncogene-mediated cell-cycle dysregulation, and distinct
    immune-checkpoint biomarker patterns.
  evidence:
  - reference: PMID:37565840
    reference_title: "Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HPV-positive and HPV-negative pSCCs are molecularly distinct tumors.
    explanation: >-
      The cohort supports HPV-associated PSCC as a molecularly distinct
      subtype.
- name: HPV-Independent PSCC
  display_name: HPV-independent penile squamous cell carcinoma
  description: >-
    Molecular subtype not driven by HPV, often linked to chronic inflammatory
    penile disease and somatic alterations affecting tumor suppressor and
    cell-cycle pathways.
  evidence:
  - reference: PMID:37565840
    reference_title: "Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HPV-positive and HPV-negative pSCCs are molecularly distinct tumors.
    explanation: >-
      This supports a distinction between HPV-positive and HPV-negative PSCC
      molecular subsets.
- name: Verrucous PSCC
  display_name: Verrucous penile squamous cell carcinoma
  description: >-
    Well-differentiated, exophytic variant with locally destructive growth and
    generally lower metastatic potential than conventional invasive PSCC.
- name: Basaloid PSCC
  display_name: Basaloid penile squamous cell carcinoma
  description: >-
    Aggressive histologic variant often associated with high-risk HPV and
    basaloid morphology.
infectious_agent:
- name: High-Risk Human Papillomavirus
  description: >-
    High-risk HPV infection contributes to a substantial subset of penile
    squamous cell carcinomas and shapes tumor biology and immune-management
    considerations.
  infectious_agent_term:
    preferred_term: Human papillomavirus 16
    term:
      id: NCBITaxon:333760
      label: Human papillomavirus 16
  evidence:
  - reference: PMID:39339000
    reference_title: "HPV and Penile Cancer: Epidemiology, Risk Factors, and Clinical Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Approximately 40% of penile tumors are associated with human
      papillomavirus (HPV) infection.
    explanation: >-
      The review directly supports HPV as a common infectious contributor to
      penile tumors.
environmental:
- name: Poor Genital Hygiene and Lack of Neonatal Circumcision
  description: >-
    Hygiene barriers and absence of neonatal circumcision are clinical risk
    contexts that can coexist with chronic local inflammation and HPV exposure.
  evidence:
  - reference: PMID:38841163
    reference_title: "A comprehensive review of current knowledge on penile squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The list of associated risk factors is long and includes among others,
      lack of neonatal circumcision, poor genital hygiene, socioeconomic status,
      history of human papillomavirus (HPV) infection and penile
      intraepithelial neoplasia (PeIN).
    explanation: >-
      This exact abstract sentence lists lack of neonatal circumcision and poor
      genital hygiene among PSCC-associated risk factors.
- name: Penile Intraepithelial Neoplasia
  description: >-
    Penile intraepithelial neoplasia is a precursor/risk lesion incorporated
    into PSCC classification and management.
  evidence:
  - reference: PMID:38841163
    reference_title: "A comprehensive review of current knowledge on penile squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HPV and PeIN are indisputable risk factors, and both also form part of the
      classification system for PSCC.
    explanation: >-
      This directly supports PeIN as a risk lesion and classification-relevant
      precursor context.
pathophysiology:
- name: HPV-Associated Epithelial Oncogenesis
  description: >-
    Persistent high-risk HPV infection promotes malignant transformation of
    penile squamous epithelium and creates an HPV-associated PSCC subset with
    distinct immune-checkpoint biomarker features.
  cell_types:
  - preferred_term: penile squamous epithelial cell
    term:
      id: CL:0000076
      label: squamous epithelial cell
  locations:
  - preferred_term: penis epithelium
    term:
      id: UBERON:0004803
      label: penis epithelium
  biological_processes:
  - preferred_term: response to virus
    modifier: ABNORMAL
    term:
      id: GO:0009615
      label: response to virus
  evidence:
  - reference: PMID:39339000
    reference_title: "HPV and Penile Cancer: Epidemiology, Risk Factors, and Clinical Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Approximately 40% of penile tumors are associated with human
      papillomavirus (HPV) infection.
    explanation: >-
      This supports HPV-associated oncogenesis as a major upstream mechanism in
      a substantial subset of penile tumors.
  - reference: PMID:37565840
    reference_title: "Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Approximately half of pSCC cases are associated with human papillomavirus
      (HPV) infection.
    explanation: >-
      The genomic cohort background independently supports frequent
      HPV-associated PSCC.
  downstream:
  - target: Invasive Squamous Cell Proliferation
    description: >-
      HPV-associated oncogenesis independently converges on malignant squamous
      proliferation rather than causing the somatic driver alterations enriched
      in HPV-negative tumors.
  - target: Immune-Checkpoint Biomarker Enrichment
    description: HPV status stratifies TMB and immune-checkpoint biomarker patterns.
- name: Somatic Cell-Cycle Driver Alteration
  description: >-
    PSCC commonly carries somatic alterations in TP53, CDKN2A, and PIK3CA,
    disrupting checkpoint control and growth/survival signaling in transformed
    penile squamous cells.
  genes:
  - preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  - preferred_term: CDKN2A
    term:
      id: hgnc:1787
      label: CDKN2A
  - preferred_term: PIK3CA
    term:
      id: hgnc:8975
      label: PIK3CA
  biological_processes:
  - preferred_term: cell cycle checkpoint signaling
    modifier: DECREASED
    term:
      id: GO:0000075
      label: cell cycle checkpoint signaling
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:37565840
    reference_title: "Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      revealed TP53 (46%), CDKN2A (26%), and PIK3CA (25%) to be the most
      common mutations.
    explanation: >-
      The NGS cohort directly supports these recurrent somatic driver genes in
      PSCC.
  downstream:
  - target: Invasive Squamous Cell Proliferation
    description: Driver alterations support malignant proliferation and invasion.
- name: Immune-Checkpoint Biomarker Enrichment
  conforms_to: "immune_checkpoint_blockade#Adaptive Immune Resistance"
  description: >-
    A substantial subset of PSCC shows PD-L1 positivity and high tumor
    mutational burden, particularly in HPV-positive tumors, providing a
    biomarker rationale for immune-checkpoint inhibitor trials.
  biological_processes:
  - preferred_term: negative regulation of T cell mediated immunity
    modifier: INCREASED
    term:
      id: GO:0002710
      label: negative regulation of T cell mediated immunity
  evidence:
  - reference: PMID:37565840
    reference_title: "Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Overall, 51% of tumors were PD-L1+, 10.7% had high TMB, and 1.1% had
      mismatch repair-deficient (dMMR)/MSI-high status.
    explanation: >-
      This supports PD-L1 and TMB as immune-checkpoint-related biomarkers in
      PSCC.
  - reference: PMID:37565840
    reference_title: "Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Increased tumor mutational burden is associated with HPV-positive tumors,
      and could serve as a biomarker for predicting therapeutic response to
      ICI-based therapies.
    explanation: >-
      This supports the HPV-associated immune biomarker rationale for
      ICI-based therapy selection.
- name: Invasive Squamous Cell Proliferation
  description: >-
    Transformed penile squamous cells proliferate locally and may disseminate
    to inguinal lymph nodes, making nodal assessment central to staging and
    prognosis.
  cell_types:
  - preferred_term: penile squamous epithelial cell
    term:
      id: CL:0000076
      label: squamous epithelial cell
  locations:
  - preferred_term: glans penis
    term:
      id: UBERON:0001299
      label: glans penis
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:38841163
    reference_title: "A comprehensive review of current knowledge on penile squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lymph node involvement is a common finding at first presentation and
      investigation of spread to deep nodes is important and can be done with
      the aid of PET-CT.
    explanation: >-
      This supports inguinal/deep nodal spread as a clinically important
      manifestation of invasive PSCC.
  - reference: PMID:39272796
    reference_title: "Minimally Invasive Management of Inguinal Lymph Nodes in Penile Cancer: Recent Progress and Remaining Challenges."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of occult inguinal lymph node metastasis in clinically
      node-negative invasive penile squamous cell carcinoma (PSCC) has remained
      a challenge, with substantial perioperative complications.
    explanation: >-
      This supports occult inguinal lymph-node metastasis as a key invasive
      disease concern.
histopathology:
- name: Squamous Cell Carcinoma Histology
  description: >-
    Squamous cell carcinoma is the dominant penile cancer histology and is
    classified further by HPV/PeIN-associated and non-HPV-related pathways and
    histologic variants.
  evidence:
  - reference: PMID:38841163
    reference_title: "A comprehensive review of current knowledge on penile squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While the penis can be affected by sarcomas, basal cell carcinomas or
      even melanoma, Penile Squamous Cell Carcinoma (PSCC) represents
      approximately 95% of all penile neoplasms.
    explanation: >-
      This supports squamous cell carcinoma as the dominant penile neoplasm
      histology.
phenotypes:
- category: Clinical
  name: Variable Penile Clinical Presentation
  description: >-
    PSCC can present in diverse clinical forms, which can delay diagnosis and
    require direct examination and biopsy of suspicious penile lesions.
  phenotype_term:
    preferred_term: variable penile clinical presentation
    term:
      id: HP:0000078
      label: Abnormality of the genital system
  evidence:
  - reference: PMID:38841163
    reference_title: "A comprehensive review of current knowledge on penile squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For such a rare condition PSCC can present in many different forms
      clinically making diagnosis no easy feat.
    explanation: >-
      This supports variable clinical presentation as a practical phenotype of
      PSCC.
- category: Clinical
  name: Primary Penile Lesion
  description: >-
    The primary clinical abnormality is a penile squamous neoplasm involving
    external male genital tissues and requiring examination and biopsy for
    classification.
  phenotype_term:
    preferred_term: primary penile lesion
    term:
      id: HP:0000032
      label: Abnormal male external genitalia morphology
  evidence:
  - reference: PMID:38841163
    reference_title: "A comprehensive review of current knowledge on penile squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Penile Squamous Cell Carcinoma (PSCC) represents approximately 95% of all
      penile neoplasms.
    explanation: >-
      This supports PSCC as a primary penile neoplastic abnormality.
- category: Clinical
  name: Inguinal Lymphadenopathy
  description: >-
    Regional nodal spread may manifest as clinically palpable inguinal
    lymphadenopathy and can also be occult in clinically node-negative invasive
    disease.
  phenotype_term:
    preferred_term: inguinal lymphadenopathy
    term:
      id: HP:0034751
      label: Inguinal lymphadenopathy
  evidence:
  - reference: PMID:38841163
    reference_title: "A comprehensive review of current knowledge on penile squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnosis of PSCC is done through clinical examination, including lymph
      node palpation, followed by a biopsy, which is essential for the
      classification.
    explanation: >-
      The diagnostic workflow includes lymph-node palpation, supporting nodal
      enlargement as a clinically assessed manifestation.
  - reference: PMID:39272796
    reference_title: "Minimally Invasive Management of Inguinal Lymph Nodes in Penile Cancer: Recent Progress and Remaining Challenges."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although DSLNB, if available, has been endorsed as the preferred method
      for nodal staging in patients with invasive PSCC and no palpable inguinal
      lymphadenopathy in the recent penile cancer guidelines, its utilization
      has been quite limited so far.
    explanation: >-
      This directly references palpable inguinal lymphadenopathy status in PSCC
      nodal staging.
genetic:
- name: TP53
  association: Somatic Driver Mutation
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  notes: >-
    TP53 is the most frequent somatic alteration reported in the 108-case PSCC
    NGS cohort.
  evidence:
  - reference: PMID:37565840
    reference_title: "Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      revealed TP53 (46%), CDKN2A (26%), and PIK3CA (25%) to be the most
      common mutations.
    explanation: >-
      This cohort identifies TP53 as the most common recurrent somatic
      alteration in PSCC.
- name: CDKN2A
  association: Somatic Driver Mutation
  gene_term:
    preferred_term: CDKN2A
    term:
      id: hgnc:1787
      label: CDKN2A
  notes: >-
    CDKN2A alteration contributes to PSCC cell-cycle pathway disruption and is
    enriched in the HPV16/18-negative subset in the cited cohort.
  evidence:
  - reference: PMID:37565840
    reference_title: "Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CDKN2A mutations (0% vs. 37.5%) were exclusive to HPV16/18- tumors.
    explanation: >-
      This supports CDKN2A mutation as a recurrent HPV-negative PSCC molecular
      feature.
- name: PIK3CA
  association: Somatic Driver Mutation
  gene_term:
    preferred_term: PIK3CA
    term:
      id: hgnc:8975
      label: PIK3CA
  notes: >-
    PIK3CA is one of the most frequent recurrent somatic mutations in the
    cited PSCC genomic cohort, supporting PI3K pathway involvement.
  evidence:
  - reference: PMID:37565840
    reference_title: "Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      revealed TP53 (46%), CDKN2A (26%), and PIK3CA (25%) to be the most
      common mutations.
    explanation: >-
      This cohort identifies PIK3CA among the most common recurrent somatic
      alterations in PSCC.
treatments:
- name: Surgical Tumor Removal
  description: >-
    Local surgical excision, glansectomy, or penectomy provides primary local
    control when disease is anatomically resectable, but can substantially
    affect quality of life.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:38841163
    reference_title: "A comprehensive review of current knowledge on penile squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Surgical removal of the tumor is considered the most effective however
      can lead to severe decrease of quality of life.
    explanation: >-
      This review supports surgery as the core local treatment and notes the
      associated quality-of-life burden.
- name: Platinum-Based Chemotherapy
  description: >-
    Platinum-based systemic chemotherapy is used for fixed or bulky nodal
    disease and distant metastatic PSCC.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
    therapeutic_agent:
    - preferred_term: platinum compound
      term:
        id: NCIT:C1450
        label: Platinum Compound
  evidence:
  - reference: PMID:38841163
    reference_title: "A comprehensive review of current knowledge on penile squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chemotherapy is used in the case of fixed or bulky lymph nodes, where
      surgery is not indicated, and for distant metastasis.
    explanation: >-
      This supports chemotherapy in advanced nodal or metastatic PSCC.
- name: Radiation Therapy
  description: >-
    Radiation therapy is used in selected PSCC contexts, with particular
    relevance in HPV-positive disease and organ-preservation strategies.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
  evidence:
  - reference: PMID:38841163
    reference_title: "A comprehensive review of current knowledge on penile squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Radiation therapy is particularly effective in the case of HPV-positive
      PSCC.
    explanation: >-
      The review supports radiation therapy as a treatment modality with
      relevance in HPV-positive PSCC.
- name: Immune Checkpoint Inhibitor Combinations
  description: >-
    Checkpoint-inhibitor combinations are investigational for advanced PSCC and
    include pembrolizumab-containing regimens motivated by PD-L1/TMB biomarker
    findings and early clinical trial experience.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: pembrolizumab
      term:
        id: NCIT:C106432
        label: Pembrolizumab
  target_mechanisms:
  - target: Immune-Checkpoint Biomarker Enrichment
    treatment_effect: MODULATES
    description: >-
      Immune-checkpoint inhibitor combinations are intended to restore
      anti-tumor immune activity in biomarker-selected or advanced PSCC.
  evidence:
  - reference: DOI:10.3390/cancers16112086
    reference_title: "Therapeutic Targets in Advanced Penile Cancer: From Bench to Bedside"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We conclude that antibody-drug conjugates are especially promising, as are
      the combinations of immune checkpoint inhibitors with other types of drugs.
    explanation: >-
      This review supports immune-checkpoint inhibitor combinations as a
      promising investigational therapeutic direction in advanced penile cancer.
  - reference: clinicaltrials:NCT04224740
    reference_title: "A Phase II Trial of Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is a phase II clinical trial evaluating activity, safety and
      patients reported outcomes of first-line pembrolizumab plus cisplatin (or
      carboplatin) plus 5-FU for patients with advanced penile squamous cell
      carcinoma.
    explanation: >-
      The trial record directly supports pembrolizumab as an immune-checkpoint
      agent used in combination therapy for advanced PSCC.
clinical_trials:
- name: NCT04224740
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Phase II HERCULES/LACOG 0218 trial of first-line pembrolizumab plus
    cisplatin or carboplatin plus 5-FU for advanced penile squamous cell
    carcinoma. ClinicalTrials.gov API listed status as COMPLETED on 2026-05-10.
  target_phenotypes:
  - preferred_term: advanced penile squamous cell carcinoma
  evidence:
  - reference: clinicaltrials:NCT04224740
    reference_title: "A Phase II Trial of Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is a phase II clinical trial evaluating activity, safety and
      patients reported outcomes of first-line pembrolizumab plus cisplatin (or
      carboplatin) plus 5-FU for patients with advanced penile squamous cell
      carcinoma.
    explanation: >-
      The ClinicalTrials.gov summary directly supports the study intervention
      and advanced PSCC population.
- name: NCT02837042
  phase: PHASE_II
  status: TERMINATED
  description: >-
    Phase II trial of pembrolizumab for advanced penile squamous cell carcinoma
    after prior chemotherapy. ClinicalTrials.gov API listed status as
    TERMINATED on 2026-05-10.
  target_phenotypes:
  - preferred_term: advanced penile squamous cell carcinoma
  evidence:
  - reference: clinicaltrials:NCT02837042
    reference_title: "Phase II Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Following Previous Chemotherapy"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Penile squamous cell carcinoma (PSCC) is relatively rare but exhibits
      higher incidences in less developed countries. PSCC is a highly
      aggressive malignancy characterized by early spread. Pembrolizumab has
      recently been FDA-approved for the treatment of melanoma but will serve as
      the investigational agent for this penile cancer study.
    explanation: >-
      The ClinicalTrials.gov summary supports pembrolizumab as the
      investigational therapy for advanced PSCC in this trial.
- name: NCT06353906
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Phase II PRIAM study of induction carboplatin/paclitaxel plus pembrolizumab
    for locoregionally advanced, node-positive, resectable squamous cell
    carcinoma of the penis. ClinicalTrials.gov API listed status as RECRUITING
    on 2026-05-10.
  target_phenotypes:
  - preferred_term: node-positive squamous cell carcinoma of the penis
  evidence:
  - reference: clinicaltrials:NCT06353906
    reference_title: "A Phase 2 Clinical Study to Assess Efficacy of Induction Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer: PRIAM"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is a single-armed, single-centre, non-blinded phase II trial to
      assess efficacy of induction chemo-immunotherapy for resectable
      node-positive squamous cell carcinoma of the penis
    explanation: >-
      The ClinicalTrials.gov summary supports the population and
      chemo-immunotherapy intervention for this recruiting phase II study.
📚

References & Deep Research

Deep Research

1
Falcon ▸
Notes on evidence gaps (transparent limitations)
Edison Scientific Literature 30 citations 2026-05-10T15:03:50.367906

1. Disease Information

1.1 Definition / overview

Penile cancer is a rare malignancy, and PSCC is the dominant histology. A 2024 review states: “Neoplasm of the penis is relatively rare in most regions representing 0–2% of cancers worldwide” and “Penile Squamous Cell Carcinoma (PSCC) represents approximately 95% of all penile neoplasms” (thumma2024acomprehensivereview pages 1-2). A 2024 systematic review similarly reports that “Approximately 95% of PeCa cases are squamous cell carcinomas (SCC)” (fadigas2024immunotherapyinpenile pages 1-2).

1.2 Key identifiers

  • MONDO: MONDO:0018352 (squamous cell carcinoma of penis) (OpenTargets Search: penile squamous cell carcinoma)
  • Other identifiers (ICD-10/ICD-11/MeSH/OMIM/Orphanet): Not retrievable from the currently indexed full texts in this tool run; therefore not reported here to avoid mislabeling.

1.3 Synonyms / alternative names

  • Penile squamous cell carcinoma (PSCC) (mannam2024hpvandpenile pages 1-2)
  • Penile cancer, penile carcinoma (when specifying SCC histology) (thumma2024acomprehensivereview pages 1-2)

1.4 Evidence provenance

The present report is derived from aggregated disease-level resources: peer‑reviewed reviews (2023–2024), a large tumor genomic profiling cohort study (2023), and ClinicalTrials.gov trial registry records (nazha2023comprehensivegenomicprofiling pages 1-2, mannam2024hpvandpenile pages 1-2, thumma2024acomprehensivereview pages 1-2, NCT06353906 chunk 1, NCT04224740 chunk 1, NCT02837042 chunk 1).

2. Etiology

2.1 Disease causal factors (mechanistic categories)

PSCC is etiologically heterogeneous and is commonly described as comprising HPV‑associated and HPV‑independent disease pathways (mannam2024hpvandpenile pages 1-2, pagliaro2024therapeutictargetsin pages 1-2).

2.2 Risk factors (human epidemiology/clinical consensus)

Infectious (HPV): - A 2024 HPV-focused review reports “Approximately 40% of penile tumors are associated with human papillomavirus (HPV) infection” (abstract wording) (mannam2024hpvandpenile pages 1-2). - The same review emphasizes HPV16 dominance and provides the HPV16 share among HPV-associated cases (46%–62.5%) (mannam2024hpvandpenile pages 5-6). - A systematic review notes “high-risk HPV... implicated in up to 50% of PeCa cases” (fadigas2024immunotherapyinpenile pages 1-2).

Genital/dermatologic/clinical: - Risk factors summarized in a 2024 review include “lack of neonatal circumcision, poor genital hygiene, socioeconomic status, history of human papillomavirus (HPV) infection and penile intraepithelial neoplasia (PeIN)” (thumma2024acomprehensivereview pages 1-2). - Phimosis is repeatedly highlighted as a major risk factor in contemporary reviews (fadigas2024immunotherapyinpenile pages 1-2, antar2024theevolvingmolecular pages 17-18).

Behavioral/environmental: - Tobacco use and sexual behavior factors (e.g., unsafe sex behavior via HPV transmission) are discussed as risk factors in 2024 summaries (mannam2024hpvandpenile pages 1-2, antar2024theevolvingmolecular pages 17-18).

2.3 Protective factors

Protective-factor effect sizes (e.g., quantitative risk reduction with circumcision or vaccination) were not present in the retrieved evidence set in this run and are therefore not quantified here. However, HPV vaccination is explicitly described as a prevention strategy (see Section 13) (mannam2024hpvandpenile pages 5-6).

2.4 Gene–environment interactions

Direct, quantitative GxE interaction studies were not identified in the retrieved evidence set for this run. Nevertheless, a biologically plausible interaction is implied by HPV-driven carcinogenesis (viral E6/E7 disruption of tumor suppressors) operating alongside host somatic alterations and immune microenvironment features (mannam2024hpvandpenile pages 5-6, nazha2023comprehensivegenomicprofiling pages 1-2).

3. Phenotypes

3.1 Clinical presentation and key phenotypic features

PSCC can present variably; diagnosis is challenging because of “variety of clinical presentations” (mannam2024hpvandpenile pages 1-2). A 2024 review notes that diagnosis often occurs late—“a common trend is for diagnosis to occur late (stage 4)” (thumma2024acomprehensivereview pages 1-2). Tumors “most commonly arise on the glans and inner prepuce” (thumma2024acomprehensivereview pages 1-2).

Locoregional spread/lymph nodes: Lymph node involvement is a common concern; “Lymph node involvement is a common finding at first presentation” and careful assessment of nodal disease is emphasized (thumma2024acomprehensivereview pages 1-2). Occult nodal metastasis risk in clinically node-negative invasive disease is estimated at ~20–25% (vreeburg2024neweauascoguideline pages 102-107).

3.2 Suggested HPO terms (examples; not exhaustive)

Because the retrieved sources were largely review-level and did not provide structured HPO mappings, the following are ontology suggestions consistent with described clinical manifestations and work-up: - Penile lesion / penile neoplasm: suggested HP:0100608 (Penile abnormality) (term-family suggestion) - Pain: suggested HP:0012531 (Pain) (general; site-specific terms may be used if available) - Inguinal lymphadenopathy: suggested HP:0002714 (Inguinal lymphadenopathy) - Sexual dysfunction / erectile dysfunction: suggested HP:0100639 (Erectile dysfunction) (QoL impact is emphasized in penile cancer care literature) (thumma2024acomprehensivereview pages 1-2)

Note: Formal frequencies per phenotype were not provided in the retrieved sources in this run.

3.3 Quality of life impact

A 2024 review highlights that surgery can “lead to severe decrease of quality of life” and that many individuals experience major QoL impact (thumma2024acomprehensivereview pages 1-2).

4. Genetic / Molecular Information

4.1 Causal genes (germline)

No single-gene germline causal model for PSCC was supported by the retrieved evidence set in this run. PSCC is primarily a malignancy driven by somatic alterations and/or HPV-associated oncogenesis (nazha2023comprehensivegenomicprofiling pages 1-2, mannam2024hpvandpenile pages 5-6).

4.2 Somatic genomic landscape (primary tumor profiling)

A large NGS cohort study profiled 108 PSCC tumors and found the most common somatic alterations were TP53 (46%), CDKN2A (26%), and PIK3CA (25%) (nazha2023comprehensivegenomicprofiling pages 1-2). This supports recurrent disruption of tumor suppression/cell cycle control (TP53, CDKN2A) and PI3K signaling.

HPV-stratified differences (subset n=29 with HPV16/18 calls): - HPV16/18-positive tumors showed enrichment of KMT2C mutations (33%) and FGF3 amplifications (30.8%). - HPV16/18-negative tumors showed more frequent CDKN2A mutations (37.5%). These subtype differences are reported in the same 2023 cohort analysis (nazha2023comprehensivegenomicprofiling pages 1-2).

4.3 Biomarkers relevant to therapy selection

In the 108-case cohort: - PD-L1 positive: 51% - TMB-high (≥10 mut/Mb): 10.7% - dMMR/MSI-high: 1.1% (nazha2023comprehensivegenomicprofiling pages 1-2)

A 2024 therapeutic-target review summarizes PD-L1 IHC positivity across studies as 33–60%, and reports that mismatch repair deficiency/MSI-H is rare; it also notes high TMB in ~18–20% overall and that one study found TMB ≥10 mut/Mb in 30.8% of HPV-related tumors and not in HPV-unrelated tumors (pagliaro2024therapeutictargetsin pages 1-2).

4.4 Epigenetic / chromosomal abnormalities

No specific PSCC epigenetic maps or recurrent structural variants were extractable from the retrieved evidence set in this run.

4.5 Suggested GO biological processes and CL cell types

Processes (GO term suggestions consistent with described mechanisms): - Viral process / viral gene expression (HPV E6/E7) (mannam2024hpvandpenile pages 5-6) - Cell cycle dysregulation; regulation of apoptotic signaling (TP53 pathway disruption) (mannam2024hpvandpenile pages 5-6, nazha2023comprehensivegenomicprofiling pages 1-2) - PI3K/AKT signaling pathway activation (via PIK3CA alterations) (nazha2023comprehensivegenomicprofiling pages 1-2) - Immune evasion / immune exclusion in tumor microenvironment (fadigas2024immunotherapyinpenile pages 1-2)

Cell types (CL term suggestions): - Keratinocytes / squamous epithelial cells (tumor cell of origin) - CD8+ T cells, FOXP3+ regulatory T cells, macrophages (CD163+) as noted in PSCC immune microenvironment descriptions (fadigas2024immunotherapyinpenile pages 1-2)

5. Environmental Information

5.1 Environmental/lifestyle factors

Reviews list tobacco use, hygiene/socioeconomic factors, and sexual behavior risk (as mediated through HPV transmission) (mannam2024hpvandpenile pages 1-2, thumma2024acomprehensivereview pages 1-2, antar2024theevolvingmolecular pages 17-18).

5.2 Infectious agents

High-risk HPV is the principal infectious contributor. The 2024 HPV-focused review discusses HPV types and states that HPV16 accounts for 46–62.5% of HPV-associated penile cancers (mannam2024hpvandpenile pages 5-6).

6. Mechanism / Pathophysiology

6.1 HPV-driven carcinogenesis (upstream triggers)

HPV-associated PSCC is driven by viral oncoproteins. The 2024 review summarizes that HPV E6 and E7 “inhibit p53 and Rb” (functional description) (mannam2024hpvandpenile pages 5-6). This provides a causal chain from persistent HR-HPV infection → E6/E7 expression → tumor suppressor pathway disruption → uncontrolled proliferation.

6.2 Somatic oncogenic pathways (HPV-independent and shared)

Somatic alterations frequently affect TP53, CDKN2A, and PI3K signaling (PIK3CA), consistent with cell-cycle deregulation and growth/survival signaling (nazha2023comprehensivegenomicprofiling pages 1-2). HPV-unrelated tumors are described as having more frequent TP53 mutation/loss and slightly worse prognosis in review synthesis (pagliaro2024therapeutictargetsin pages 1-2).

6.3 Immune microenvironment and therapy-relevant biology

A 2024 systematic review describes PSCC as often “immune excluded” with stromal enrichment of immune cells, including CD8+ and FOXP3+ cells, and notes higher CD163+ macrophage density in HPV-positive tumors (fadigas2024immunotherapyinpenile pages 1-2). These features motivate investigation of checkpoint inhibitors and combinations (pagliaro2024therapeutictargetsin pages 1-2).

7. Anatomical Structures Affected

7.1 Organ/tissue level

Primary sites commonly include glans and inner prepuce (thumma2024acomprehensivereview pages 1-2).

Regional spread: predictable stepwise spread to inguinal nodes is emphasized in nodal-management reviews; occult metastases in cN0 invasive cases are ~20–25% (vreeburg2024neweauascoguideline pages 102-107).

7.2 Suggested UBERON terms (examples)

  • Penis: suggested UBERON:0000989
  • Glans penis: suggested UBERON term for glans penis
  • Inguinal lymph node: suggested UBERON:0001542 (inguinal lymph node)

8. Temporal Development

8.1 Onset

PSCC is “most commonly diagnosed in older men” (review summary) (pagliaro2024therapeutictargetsin pages 1-2), and one review reports mean age at diagnosis 67 years in the U.S. context (mannam2024hpvandpenile pages 1-2).

8.2 Progression / staging-related course

Late presentation is common (“diagnosis… late (stage 4)”) (thumma2024acomprehensivereview pages 1-2). Prognosis is strongly driven by depth of invasion and nodal/metastatic status (mannam2024hpvandpenile pages 1-2).

9. Inheritance and Population

9.1 Epidemiology (recent quantitative points)

  • Global penile cancer age-standardized incidence in 2020: 0.8 per 100,000 (mannam2024hpvandpenile pages 1-2).
  • U.S. incidence reported as 0.38 per 100,000 (mannam2024hpvandpenile pages 1-2).
  • U.S. burden estimate: ~2,100 new cases and 500 deaths annually (antar2024theevolvingmolecular pages 17-18).
  • High-incidence examples include India (up to 3.32/100,000) and Northeast Brazil (6.1/100,000; 5.7% of male neoplasms) (mannam2024hpvandpenile pages 1-2).

9.2 Genetic inheritance

No Mendelian inheritance pattern is supported for PSCC in the retrieved evidence set; PSCC is primarily sporadic/somatic with infectious contributions (nazha2023comprehensivegenomicprofiling pages 1-2, mannam2024hpvandpenile pages 1-2).

10. Diagnostics

10.1 Clinical and pathology diagnosis

A 2024 review states: “Diagnosis of PSCC is done through clinical examination… followed by a biopsy, which is essential for the classification” (thumma2024acomprehensivereview pages 1-2). Nodal evaluation is critical; PET-CT is mentioned as aiding deep-node evaluation (thumma2024acomprehensivereview pages 1-2).

10.2 Biomarker/pathology adjuncts

p16INK4a is described as an HPV-associated marker; in one 2024 review summary, p16INK4a is reported as overexpressed in HPV lesions and “has 100% specificity and positive predictive value” (mannam2024hpvandpenile pages 1-2).

10.3 Lymph node staging innovations (real-world implementations)

The 2023 intercontinental EAU/ASCO update is summarized as recommending dynamic sentinel node biopsy (DSNB) as the preferred method for nodal staging in selected patients (≥T1b) (vreeburg2024neweauascoguideline pages 102-107). Quantitative DSNB metrics reported in the 2024 review include a large-cohort false-negative rate of “8.7% per groin” and a 2-year probability of a negative DSNB later being a false-negative procedure of 2.5% (1.4% per groin) (vreeburg2024neweauascoguideline pages 102-107). Reported DSNB morbidity metrics include overall complications 22% and major complications 3% in one review summary, with wound infection ~10% and lymphocele ~3% (aydin2024minimallyinvasivemanagement pages 2-4).

11. Outcome / Prognosis

11.1 Prognostic factors

A 2024 review indicates that “tumor size, invasion, nodal status, and metastases are primary prognostic factors” (mannam2024hpvandpenile pages 1-2). HPV-associated histologic subtypes are described as conferring markedly higher nodal involvement risk (a “28-fold increased relative risk of inguinal lymph node involvement”) (mannam2024hpvandpenile pages 1-2).

11.2 Survival statistics

Robust stage-stratified 5- and 10-year OS/CSS statistics were not extractable from the retrieved evidence set in this run; therefore they are not reported to avoid inaccuracies.

12. Treatment

12.1 Standard modalities (current understanding)

A 2024 review states: “Surgical removal of the tumor is considered the most effective” but can significantly reduce quality of life; chemotherapy is used for “fixed or bulky lymph nodes… and for distant metastasis,” and radiation therapy is “particularly effective in the case of HPV-positive PSCC” (thumma2024acomprehensivereview pages 1-2). Contemporary therapy reviews note that the systemic backbone for unresectable/metastatic disease remains cisplatin-based chemotherapy or chemoradiotherapy, with growing exploration of targeted therapy and immune checkpoint inhibition (pagliaro2024therapeutictargetsin pages 1-2).

12.2 Immunotherapy evidence and expert synthesis

A 2024 systematic review emphasizes limited trial-result availability and reports that only one qualifying phase-2 study met inclusion criteria, with an “objective response rate… 6% across nineteen patients” (basket of histologies; only 6 penile cases) (fadigas2024immunotherapyinpenile pages 1-2). A 2024 therapeutic-target review concludes that antibody–drug conjugates and ICI combinations are promising directions (pagliaro2024therapeutictargetsin pages 1-2).

12.3 Real-world implementations: nodal management

Because outcomes are highly dependent on nodal metastasis, DSNB and minimally invasive approaches to inguinal lymph node management are emphasized as pragmatic strategies to reduce morbidity while improving staging accuracy (vreeburg2024neweauascoguideline pages 102-107, aydin2024minimallyinvasivemanagement pages 2-4).

12.4 Active/recent clinical trials (ClinicalTrials.gov; key NCTs)

Pembrolizumab + chemotherapy combinations: - NCT04224740 (HERCULES; LACOG 0218): Phase II, single-group; pembrolizumab 200 mg q3w plus platinum (cisplatin 70 mg/m² D1 or carboplatin AUC 5) + 5‑FU (1000 mg/m²/day D1–4) q3w for 6 cycles; 37 participants; completed 2023‑11‑13 (registry) (NCT04224740 chunk 1). - NCT06353906 (PRIAM): Phase II induction carboplatin/paclitaxel plus pembrolizumab (400 mg on cycles 1 and 3) for node-positive resectable disease, followed by consolidative surgery and adjuvant pembrolizumab; primary endpoint pCR; recruiting (NCT06353906 chunk 1).

Single-agent pembrolizumab (advanced PSCC): - NCT02837042: Phase II pembrolizumab after prior chemotherapy; enrolled 6; terminated for poor accrual (NCT02837042 chunk 1).

EGFR-directed antibody–drug conjugate + PD-1 combinations (emerging targeted therapy): - NCT07054307: Phase I in EGFR-positive unresectable/metastatic PSCC; MRG003 (EGFR-ADC) + HX008 (PD‑1); planned n=10; recruiting (NCT07054307 chunk 2). - NCT07518979: Phase II neoadjuvant EGFR-ADC (becotatug vedotin) + PD‑1 inhibitor (pucotenlimab) in advanced PSCC with penile-preservation difficulty or regional nodal metastasis; not yet recruiting (estimated start 2026) (NCT07518979 chunk 1).

12.5 Suggested MAXO terms (examples)

  • Surgical excision / penectomy / glansectomy (local control) (thumma2024acomprehensivereview pages 1-2)
  • Radiotherapy (organ preservation; HPV-associated radiosensitivity discussion) (thumma2024acomprehensivereview pages 1-2, mannam2024hpvandpenile pages 5-6)
  • Chemotherapy (cisplatin-based) (advanced disease) (thumma2024acomprehensivereview pages 1-2, NCT04224740 chunk 1)
  • Immune checkpoint inhibitor therapy (anti–PD‑1) (trialed/ongoing) (NCT02837042 chunk 1, NCT04224740 chunk 1)
  • Sentinel lymph node biopsy / lymph node dissection (staging/management) (vreeburg2024neweauascoguideline pages 102-107)

13. Prevention

13.1 Primary prevention

HPV vaccination: A 2024 review notes prophylactic vaccines protecting against high-risk HPV16/18 (e.g., Gardasil 9) and states ACIP recommends vaccination for boys aged 11–12 with catch-up through 21 (mannam2024hpvandpenile pages 5-6). Given the fraction of PSCC that is HPV-associated (≈38.5–40% in one review), vaccination is a plausible population-level prevention lever (mannam2024hpvandpenile pages 1-2).

13.2 Secondary prevention

No population-wide screening program evidence was extractable from this run; however, timely clinical evaluation and biopsy-based diagnosis are emphasized (thumma2024acomprehensivereview pages 1-2).

14. Other Species / Natural Disease

No naturally occurring veterinary PSCC analogs or zoonotic considerations were identified in the retrieved evidence set in this run.

15. Model Organisms

No model organism systems (genetically engineered mouse models, organoids, etc.) were identified in the retrieved evidence set in this run.

Notes on evidence gaps (transparent limitations)

  1. ICD/MeSH/OMIM/Orphanet identifiers were not extractable from the retrieved full texts in this run; only MONDO identifiers were obtained through an ontology resource (OpenTargets). (OpenTargets Search: penile squamous cell carcinoma)
  2. Stage-stratified survival outcomes (e.g., 5-year OS/CSS by stage) were not present in the retrieved evidence set and thus are not provided.
  3. Protective-factor effect sizes (circumcision/vaccination quantitative risk reduction) and gene–environment interaction studies were not identified in the retrieved evidence set.

Retrieved visual evidence

A table image summarizing approximate frequencies of PSCC histologic subtypes was retrieved from Thumma et al. 2024 (Frontiers in Oncology) and can be used for knowledge-base subtype frequency curation (thumma2024acomprehensivereview media 89cd9d95).

References

  1. (OpenTargets Search: penile squamous cell carcinoma): Open Targets Query (penile squamous cell carcinoma, 0 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  2. (thumma2024acomprehensivereview pages 1-2): Nishanth Thumma, Neharaj Pitla, Vasavi Gorantla, and Maira du Plessis. A comprehensive review of current knowledge on penile squamous cell carcinoma. Frontiers in Oncology, May 2024. URL: https://doi.org/10.3389/fonc.2024.1375882, doi:10.3389/fonc.2024.1375882. This article has 21 citations.

  3. (mannam2024hpvandpenile pages 1-2): Gowtam Mannam, Justin W. Miller, Jeffrey S. Johnson, Keerthi Gullapalli, Adnan Fazili, Philippe E. Spiess, and Jad Chahoud. Hpv and penile cancer: epidemiology, risk factors, and clinical insights. Pathogens, 13:809, Sep 2024. URL: https://doi.org/10.3390/pathogens13090809, doi:10.3390/pathogens13090809. This article has 26 citations.

  4. (antar2024theevolvingmolecular pages 17-18): Ryan Michael Antar, Christopher Fawaz, Diego Gonzalez, Vincent Eric Xu, Arthur Pierre Drouaud, Jason Krastein, Faozia Pio, Andeulazia Murdock, Kirolos Youssef, Stanislav Sobol, and Michael J. Whalen. The evolving molecular landscape and actionable alterations in urologic cancers. Current Oncology, 31:6909-6937, Nov 2024. URL: https://doi.org/10.3390/curroncol31110511, doi:10.3390/curroncol31110511. This article has 6 citations.

  5. (pagliaro2024therapeutictargetsin pages 1-2): Lance C Pagliaro, Burak Tekin, Sounak Gupta, and Loren P Herrera Hernandez. Therapeutic targets in advanced penile cancer: from bench to bedside. Cancers, 16:2086, May 2024. URL: https://doi.org/10.3390/cancers16112086, doi:10.3390/cancers16112086. This article has 15 citations.

  6. (mannam2024hpvandpenile pages 5-6): Gowtam Mannam, Justin W. Miller, Jeffrey S. Johnson, Keerthi Gullapalli, Adnan Fazili, Philippe E. Spiess, and Jad Chahoud. Hpv and penile cancer: epidemiology, risk factors, and clinical insights. Pathogens, 13:809, Sep 2024. URL: https://doi.org/10.3390/pathogens13090809, doi:10.3390/pathogens13090809. This article has 26 citations.

  7. (fadigas2024immunotherapyinpenile pages 1-2): Filipe Fadigas, Diana Martins, and Fernando Mendes. Immunotherapy in penile cancer: a systematic review. Archivos espanoles de urologia, 77 10:1102-1111, Dec 2024. URL: https://doi.org/10.56434/j.arch.esp.urol.20247710.154, doi:10.56434/j.arch.esp.urol.20247710.154. This article has 0 citations.

  8. (nazha2023comprehensivegenomicprofiling pages 1-2): Bassel Nazha, Tony Zhuang, Sharon Wu, Jacqueline T. Brown, Daniel Magee, Bradley C. Carthon, Omer Kucuk, Chadi Nabhan, Pedro C. Barata, Elisabeth I. Heath, Charles J. Ryan, Rana R. McKay, Viraj A. Master, and Mehmet Asim Bilen. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune‐checkpoint inhibitor‐related biomarkers. Cancer, 129:3884-3893, Aug 2023. URL: https://doi.org/10.1002/cncr.34982, doi:10.1002/cncr.34982. This article has 45 citations and is from a domain leading peer-reviewed journal.

  9. (vreeburg2024neweauascoguideline pages 102-107): Manon T. A. Vreeburg, Maarten L. Donswijk, Maarten Albersen, Arie Parnham, Benjamin Ayres, Chris Protzel, Curtis Pettaway, Philippe E. Spiess, and Oscar R. Brouwer. New eau/asco guideline recommendations on sentinel node biopsy for penile cancer and remaining challenges from a nuclear medicine perspective. European journal of nuclear medicine and molecular imaging, 51:2861-2868, Jan 2024. URL: https://doi.org/10.1007/s00259-023-06586-6, doi:10.1007/s00259-023-06586-6. This article has 7 citations and is from a highest quality peer-reviewed journal.

  10. (vreeburg2024neweauascoguideline pages 110-113): Manon T. A. Vreeburg, Maarten L. Donswijk, Maarten Albersen, Arie Parnham, Benjamin Ayres, Chris Protzel, Curtis Pettaway, Philippe E. Spiess, and Oscar R. Brouwer. New eau/asco guideline recommendations on sentinel node biopsy for penile cancer and remaining challenges from a nuclear medicine perspective. European journal of nuclear medicine and molecular imaging, 51:2861-2868, Jan 2024. URL: https://doi.org/10.1007/s00259-023-06586-6, doi:10.1007/s00259-023-06586-6. This article has 7 citations and is from a highest quality peer-reviewed journal.

  11. (aydin2024minimallyinvasivemanagement pages 2-4): Ahmet Murat Aydin, Emily Biben, Alice Yu, Nicholas H. Chakiryan, Reza Mehrazin, and Philippe E. Spiess. Minimally invasive management of inguinal lymph nodes in penile cancer: recent progress and remaining challenges. Cancers, 16:2935, Aug 2024. URL: https://doi.org/10.3390/cancers16172935, doi:10.3390/cancers16172935. This article has 6 citations.

  12. (NCT04224740 chunk 1): Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer. Latin American Cooperative Oncology Group. 2020. ClinicalTrials.gov Identifier: NCT04224740

  13. (NCT02837042 chunk 1): Lisle Nabell. Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma. University of Alabama at Birmingham. 2016. ClinicalTrials.gov Identifier: NCT02837042

  14. (NCT06353906 chunk 1): Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer. The Netherlands Cancer Institute. 2024. ClinicalTrials.gov Identifier: NCT06353906

  15. (NCT07054307 chunk 2): Jiyan Liu. MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma. Jiyan Liu. 2026. ClinicalTrials.gov Identifier: NCT07054307

  16. (NCT07518979 chunk 1): Jiyan Liu. EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer. Jiyan Liu. 2026. ClinicalTrials.gov Identifier: NCT07518979

  17. (thumma2024acomprehensivereview media 89cd9d95): Nishanth Thumma, Neharaj Pitla, Vasavi Gorantla, and Maira du Plessis. A comprehensive review of current knowledge on penile squamous cell carcinoma. Frontiers in Oncology, May 2024. URL: https://doi.org/10.3389/fonc.2024.1375882, doi:10.3389/fonc.2024.1375882. This article has 21 citations.